Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 07 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 18 Nov 2018 New trial record